ZFPL1 Activators
ZFPL1 can influence its activity through various pathways that converge on the modulation of cyclic AMP (cAMP) levels and the activation of protein kinase A (PKA). Forskolin, for example, directly stimulates adenylyl cyclase, the enzyme responsible for the synthesis of cAMP from ATP. This elevation in cAMP facilitates the activation of PKA, a key player in phosphorylation events within the cell. Similarly, Isoproterenol, a beta-adrenergic agonist, and Salbutamol as well as Terbutaline, both beta-2 adrenergic receptor agonists, initiate their effects by binding to their respective receptors, leading to the activation of adenylyl cyclase and a subsequent rise in cAMP levels. As cAMP accumulates, PKA is activated and can phosphorylate various target proteins, including ZFPL1.
IBMX and Rolipram, by inhibiting phosphodiesterases, prevent the breakdown of cAMP, thereby indirectly contributing to the activation of PKA. Anagrelide and Cilostamide, through their inhibition of phosphodiesterase 3A and 3 respectively, also result in increased cAMP levels, further promoting PKA activity. On the other hand, compounds like Epinephrine and Dopamine exert their effects via interaction with their specific receptors that are coupled to G proteins, which in turn stimulate adenylyl cyclase, amplifying cAMP production. Prostaglandin E1 (PGE1) activates adenylate cyclase through its own G protein-coupled receptor, also upregulating cAMP. Histamine, engaging with H2 receptors, follows a similar route leading to increased cAMP. The cascade of events following the rise in cAMP, primarily the activation of PKA, culminates in the phosphorylation of target proteins, thereby modulating the activity of ZFPL1.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that leads to the activation of adenylyl cyclase and increased production of cAMP. The cAMP acts as a second messenger to activate PKA, which may then phosphorylate and activate ZFPL1 as part of the cAMP-dependent signaling pathway. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, enzymes that break down cAMP. By preventing cAMP degradation, IBMX indirectly increases the activity of PKA, which could then phosphorylate ZFPL1, thereby promoting its activation. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine, also known as adrenaline, interacts with beta-adrenergic receptors, stimulating adenylyl cyclase, and subsequently increasing cAMP levels. The activation of PKA that follows can lead to the phosphorylation and activation of proteins like ZFPL1 in the signaling cascade. | ||||||
PGE1 (Prostaglandin E1) | 745-65-3 | sc-201223 sc-201223A | 1 mg 10 mg | $31.00 $145.00 | 16 | |
Prostaglandin E1 (PGE1) activates adenylate cyclase via its G protein-coupled receptor leading to an increase in cAMP levels. This rise in cAMP can activate PKA, which in turn may phosphorylate and activate ZFPL1. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which degrades cAMP. By inhibiting PDE4, rolipram increases cAMP levels, thereby activating PKA, which potentially leads to the activation of ZFPL1 through phosphorylation. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits phosphodiesterase 3A (PDE3A), leading to increased cAMP levels. Elevated cAMP can activate PKA, which may result in the phosphorylation and activation of ZFPL1. | ||||||
Salbutamol | 18559-94-9 | sc-253527 sc-253527A | 25 mg 50 mg | $94.00 $141.00 | ||
Salbutamol is a beta-2 adrenergic receptor agonist that induces the production of cAMP by activating adenylyl cyclase. The increased cAMP levels activate PKA, which may phosphorylate and activate ZFPL1 as part of the signaling response. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Histamine can stimulate H2 receptors, which are coupled to adenylyl cyclase via Gs proteins, leading to increased cAMP levels. The subsequent activation of PKA may phosphorylate and activate ZFPL1 as part of the cellular response to histamine. | ||||||
Dopamine | 51-61-6 | sc-507336 | 1 g | $290.00 | ||
Dopamine can bind to D1-like receptors, which are coupled to adenylyl cyclase, increasing cAMP levels. The activation of PKA following this rise in cAMP could lead to phosphorylation and activation of ZFPL1 in dopaminergic signaling pathways. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $92.00 $378.00 | 2 | |
Terbutaline activates beta-2 adrenergic receptors, leading to increased cAMP production via adenylyl cyclase activation. This increase in cAMP levels can activate PKA, which in turn may phosphorylate and activate ZFPL1. | ||||||